Dr. Patrick Harris 

Dr Patrick Harris is an Infectious Disease Physician, Medical Microbiologist and NHMRC Early Career Fellow at The University of Queensland Centre for Clinical Research (UQCCR). 

His research has a focus on antibiotic resistant bacteria and the use of randomised clinical trials to define optimal treatment for these problematic infections as well as the application of microbial genomics to clinical practice. 

Dr. Burcu Isler

Dr Burcu Isler is an Infectious Diseases Physician at Princess Alexandra Hospital and a PhD candidate at the University of Queensland Centre for Clinical Research in Brisbane. Dr Isler obtained her medical degree from Hacettepe School of Medicine and specialist in infectious disease and clinical microbiology degree from Istanbul Training and Research Hospital, Turkey. Her research interests include novel antimicrobials against multidrug resistant bacteria, OXA-48/NDM producing Klebsiella pneumoniae, bloodstream infections due to carbapenem resistant Enterobacterales, and orthopaedic device related infections. 

Dr. David Grolman 

Dr David Grolman is the COVID-19/Flu Vaccines and Antivirals Medical Lead of Pfizer Australia and New Zealand. He is a qualified surgeon and intensivist who previously was in clinical practice for 20 years prior to joining the pharmaceutical industry. David is a Steering Committee member of the national Australian Antimicrobial Resistance Network, a public-private partnership committed to sourcing AMR solutions for Australia and to drive AMS initiatives locally. 

Pfizer 

Every day, Pfizer colleagues work to provide improved health outcomes by supporting preventions, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as a World leading biopharmaceutical company, we collaborate with healthcare providers, governments and local communities to support and expand access to reliable and affordable health care for the community. 

Pfizer Anti-Infectives has undertaken to prioritise research, education and drug development initiatives designed to help address the critical need for novel antimicrobial medicines, a better understanding of bacterial antibiotic resistance and projects to enhance antimicrobial stewardship. Please visit us at www.pfizer.com.au